Clinical trials: Ophthalmic Solutions
Corneal Epithelial Disorders
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02104388
- Testing
- SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
- Where
- 17 sites in United States
- Volunteers
- 69 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Keratoconus, Pellucid Marginal Corneal Degeneration
Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
- Conditions
- Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
- Trial name
- NCT04177082
- Testing
- PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cornea Associates of Texas
Glaucoma, Glaucoma, Open-Angle
Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients
The purpose of this study is to evaluate the effect of microdrops vs. standard eyedrops of 0.5% timolol maleate in adults with primary open-angle glaucoma or ocular hypertension in terms of intraocular pressure-lowering efficacy…
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Glaucoma, Primary Open Angle, Glaucoma and Ocular Hypertension
- Trial name
- NCT05181046
- Testing
- Nanodropper adaptor, Original eyedrop bottle/No Nanodropper
- Where
- 2 sites in India
- Volunteers
- 420 people
- Sponsor
- Nanodropper, Inc.
Myopia, Progressive
Atropine 0.01% Eye Drops in Myopia Study
Control of myopia progression has become an important goal because of concerns regarding significantly increased risks of retinal degeneration, retinal detachment, glaucoma and cataract associated with high myopia.
- Trial name
- AIMS (NCT03508817)
- Testing
- Atropine Sulfate 0.01% Eye Drops
- Where
- Oman
- Volunteers
- 150 people
- Sponsor
- Sultan Qaboos University
Non-arteritic Ischemic Optic Neuropathy
Citicoline in Non-Arteritic Ischemic Optic Neuropathy
The investigators tested the hypothesis whether the treatment with Citicoline in oral solution (OS-Citicoline) would increase or stabilize visual acuity, retinal ganglion cells (RGCs) function and neural conduction along the…
- Trial name
- NCT03758118
- Testing
- Citicoline
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Diabetic Macular Edema
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
This is an investigator-sponsored trial (IST), an open-label pilot study, assessing the safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.
- Trial name
- NCT00491166
- Testing
- Bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Boston
Dry Eye Syndrome
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT02597803
- Testing
- RGN-259
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- ReGenTree, LLC
Healthy Cornea
Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution Administration
The goal of this clinical trial is to evaluate the corneal endothelium health of eyes treated with articaine ophthalmic solution in adult participants.
- Trial name
- NCT07838129
- Testing
- Articaine (CYKLX), Vehicle
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Laboratoires Thea
Glaucoma, Ocular Hypertension
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in…
- Trial name
- NCT01658839
- Testing
- Travoprost ophthalmic solution, 0.004% (new formulation)
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
- Trial name
- NCT03982368
- Testing
- rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 261 people
- Sponsor
- Dompé Farmaceutici S.p.A
Myopia, Astigmatism
Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems
The purpose of this study is to evaluate the lipid uptake, wetting characteristics, and visual performance of AIR OPTIX® AQUA and ACUVUE® OASYS® with HYDRACLEAR® contact lenses when used in conjunction with two contact lens care…
- Conditions
- Myopia, Astigmatism, Refractive Error
- Trial name
- NCT01699750
- Testing
- Lotrafilcon B contact lenses, Senofilcon A contact lenses, OPTI-FREE® PUREMOIST® MPDS
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Alcon Research
Non-Infectious Anterior Uveitis
Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis
The goal of this clinical trial is to assess the safety and tolerability of Oftac in active non-infectious anterior uveitis patients. The main questions it aims to answer are: 1.
- Trial name
- NCT07869953
- Testing
- Oftac: 0.05% tacrolimus ophthalmic emulsion
- Where
- 7 sites in Israel
- Volunteers
- 18 people
- Sponsor
- BioNanoSim Ltd.
Allergic Conjunctivitis, Seasonal Allergies
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal…
- Trial name
- NCT02578914
- Testing
- NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension…
- Trial name
- NCT04620135
- Testing
- Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Where
- Japan
- Volunteers
- 245 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Graft vs Host Disease, Dry Eye
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
- Trial name
- NCT02702518
- Testing
- rhDNase I, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Illinois Chicago
Hyperemia Eye
Safety and Tolerability of PRO-185
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
- Trial name
- PRO-185 (NCT05470868)
- Testing
- Naphazoline / Hypromellose Ophthalmic
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease
A Study Designed to Evaluate Tear Production
The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
- Trial name
- NCT06544707
- Testing
- 0.003% AR-15512 ophthalmic solution
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
- Trial name
- NCT05733624
- Testing
- SCAI-001 0.01% eyedrop, SCAI-001 0.02% eyedrop, Restasis 0.05% eyedrop
- Where
- 11 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- SCAI Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.